JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
View original at finance.yahoo.comJNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now? Johnson & Johnson JNJ and Pfizer PFE are both healthcare leaders with large drug portfolios and diversified revenue streams, making them direct peers in the blue-chip healthcare space…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Pfizer expects significant impact from loss of patent exclusivity in 2026-2030 period as several key products face patent expirations
80% confidenceJ&J expects accelerated growth in both Innovative Medicine and MedTech segments in 2026
80% confidenceJ&J believes nipocalimab has pipeline-in-a-product potential
80% confidenceJ&J looks quite confident that it will be able to navigate challenges despite headwinds
80% confidencePfizer expects unfavorable impact of approximately $1 billion from Medicare Part D redesign under Inflation Reduction Act
80% confidenceJ&J expects continued impacts from VBP issues in China as the program continues to expand across provinces and products
80% confidenceJ&J believes icotrokinra has the potential to revolutionize the treatment of plaque psoriasis with a once-a-day pill
80% confidencePfizer expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027
80% confidencePfizer expects 2025 to 2030 revenue CAGR to be approximately 6%
80% confidence10 of J&J's new products/pipeline candidates in Innovative Medicine segment have potential to deliver peak sales of $5 billion
80% confidenceJ&J is a better pick than Pfizer based on improving growth prospects, price appreciation, and rising estimates
80% confidence